Upload
danimmano854
View
236
Download
0
Embed Size (px)
Citation preview
8/3/2019 Nanostructure-Mediated Drug Delivery
1/20
Nanostructure-MediatedDrug Delivery
Gareth A. Hughes, PhD
The predominant methods to deliver drugs are oral and injection, whichhas limited the progress of drug development. Most drugs have been
formulated to accommodate the oral or injection delivery routes, which
are not always the most efficient routes for a particular therapy. Newbiologic drugs such as proteins and nucleic acids require novel delivery
technologies that will minimize side effects and lead to better patientcompliance.1,2 Market forces are also driving the need for new, effective
drug delivery methods.3 It is estimated that drug delivery will account for
39% of all pharmaceutical sales by 2007.4 Meanwhile, upcoming patentexpirations are driving pharmaceutical companies to reformulate their
products. New drug delivery methods may enable pharmaceutical com-panies to develop new formulations of off-patent and soon-to-be off-
patent drugs. Reformulating old drugs can reduce side effects andincrease patient compliance, thus saving money on health care delivery.Furthermore, drug candidates that did not pass through the trials phases
may be reformulated to be used with new drug delivery systems.Innovative drug delivery systems may make it possible to use certain
chemical entities or biologics that were previously impractical because of
toxicities or because they were impossible to administer. For example,drug targeting is enabling the delivery of chemotherapy agents directly to
tumors, reducing systemic side effects. Researchers are continuallyinvestigating new ways to deliver macromolecules that will facilitate the
development of new biologic products such as bioblood proteins and
biovaccines. Similarly, the success of DNA and RNA therapies willdepend on innovative drug delivery techniques.5 Many times, the success
of a drug is dependent on the delivery method. This importance isexemplified by the presence of more than 300 companies based in the
United States involved with developing drug delivery platforms.6
Reprinted with permission from Nanomedicine: Nanotechnology, Biology, and Medicine (2005;1:23-30). 2005 Elsevier Inc.
Dis Mon 2005;51:342-3610011-5029/2005 $30.00 0doi:10.1016/j.disamonth.2005.08.004
342 DM, June 2005
8/3/2019 Nanostructure-Mediated Drug Delivery
2/20
Drug Delivery AlternativesIn addition to the commonly used oral and injection routes, drugs can also
be administered through other means, including transdermal, transmuco-
sal, ocular, pulmonary, and implantation. The mechanisms used toachieve alternative drug delivery typically incorporate one or more of the
following materials: biologics, polymers, silicon-based materials, carbon-based materials, or metals. These materials are structured in microscale
and, more recently, nanoscale formats. Table 1 summarizes the materials
and structures currently being investigated at the nanoscale for drugdelivery applications.
Nanotechnology and Drug DeliveryThe US National Nanotechnology Initiative (NNI), initiated in October
2000, provides a federal vision for nanotechnology-based investmentthrough the coordination of 16 US departments and independent agencies.
Ten potential research and development targets by 2015 for the NNI areshown in Table 2.7
TABLE 1. Nanoscale drug delivery technologies
Drug Delivery
TechnologyMaterials Nanostructure Forms
Biologic Lipids Vesicles, nanotubes, rings
Peptides Nanoparticles
Nucleic acids
Polysaccharides
Viruses
Polymeric Poly(lactic acid) Vesicles, spheres, nanoparticles
Poly(glycolic acid) Micelles, dendrimers
Poly(alkylcyanoacrylate)
Poly(3-hydroxybutanoic acid)
Poly(organophosphazene)
Poly(ethylene glycol)Poly(caprolactone)
Poly(ethylene oxide)
Poly(amidoamine)
Poly(L-glutamic acid)
Poly(ethyleneimine)
Poly(propylene imine)
Silicon based Silicon Porous, nanoparticles
Silicon dioxide Nanoneedles
Carbon based Carbon Nanotubes, fullerness
Metallic Gold Nanoparticles, nanoshells
Silver
Palladium
Platinum
DM, June 2005 343
8/3/2019 Nanostructure-Mediated Drug Delivery
3/20
Five of these research and development targets are relevant to drugdevelopment and delivery: no suffering and death from cancer when
treated, advanced materials and manufacturing, pharmaceutical synthesis
and delivery, converging technologies from the nanoscale, and life-cyclebiocompatible/sustainable development. This emphasis exemplifies the
importance of nanotechnology in the progress of medicine.The efficiency of drug delivery to various parts of the body is directly
affected by particle size. Nanostructure-mediated drug delivery, a key
technology for the realization of nanomedicine, has the potential toenhance drug bioavailability, improve the timed release of drug mole-
cules, and enable precision drug targeting.8,9 Nanoscale drug deliverysystems can be implemented within pulmonary therapies,10 as gene
delivery vectors,11 and in stabilization of drug molecules that would
otherwise degrade too rapidly.12,13 Additional benefits of using targetednanoscale drug carriers are reduced drug toxicity and more efficient drug
distribution.14
Anatomic features such as the blood brain barrier, the branchingpathways of the pulmonary system, and the tight epithelial junctions of
the skin make it difficult for drugs to reach many desired physiologictargets. Nanostructured drug carriers will help to penetrate or overcome
these barriers to drug delivery. Courrier et al.10 have shown that the
greatest efficiency for delivery into the pulmonary system is achieved forparticle diameters of100 nm. Greater uptake efficiency has also been
shown for gastrointestinal absorption15,16 and transcutaneous perme-
ation,17 with particles around 100 nm and 50 nm in size, respectively.However, such small particles traveling in the pulmonary tract may also
have a greater chance of being exhaled. Larger, compartmental ormultilayered drug carrier architectures may help with delivery to the
pulmonary extremities. For instance, the outer layers of the carrierarchitecture may be formulated to biodegrade as the carrier travels
TABLE 2. Potential R&D targets by 2015 for U.S. National Nanotechnology Initiative
Nanoscale visualization and simulation of 3-dimensional domains
Transistor beyond/integrated CMOS 10 nm
New catalysts for chemical manufacturingNo suffering and death from cancer when treated
Control of nanoparticles in air, soils, and waters
Advanced materials and manufacturing: one-half from molecular level
Pharmaceuticals synthesis and delivery: one-half on nanoscale level
Converging technologies from nanoscale
Life-cycle biocompatible/sustainable development
Education: nanoscale instead of microscale based
344 DM, June 2005
8/3/2019 Nanostructure-Mediated Drug Delivery
4/20
through the pulmonary tract. As the drug carrier penetrates further into the
lung, additional shedding will allow the encapsulated drug to be released.
Biodegradable nanoparticles of gelatin and human serum albumin showpromise as pulmonary drug carriers.18
Advantages of nanostructure-mediated drug delivery include the ability
to deliver drug molecules directly into cells19 and the capacity to target
tumors within healthy tissue.20 For example, DNA and RNA that is
packaged within a nanoscale delivery system can be transported into the
cell to fix genetic mutations or alter gene expression profiles. The
mechanisms of cellular uptake of external particulates include clathrin-
and caveoli-mediated endocytosis, pinocytosis, and phagocytosis. How-ever, phagocytosis may not play a role in the uptake of nanoscale particles
because of the small size of such particles.21
Nanoscale drug delivery architectures are able to penetrate tumors due
to the discontinuous, or leaky, nature of the tumor microvasculature,
which typically contains pores ranging from 100 to 1000 nm in diameter.
The microvasculature of healthy tissue varies by tissue type, but in most
tissues including the heart, brain, and lung, there are tight intercellular
junctions less than 10 nm. Therefore, tumors within these tissue types canbe selectively targeted by creating drug delivery nanostructures greater
than the intercellular gap of the healthy tissue but smaller than the pores
found within the tumor vasculature.
Through precise control of the drug carrier architecture, the release of
the drug can be tuned to achieve a desired kinetic profile. Three of the
most common kinetic profiles are zero order, first order, and Higuchi;
these are depicted in Figure 1 and expressed mathematically in Eq. (1).
The delivery of most drugs is accomplished through oral administrationor by injection and follows first-order kinetics. The ideal release profile
for most drugs would follow a steady release rate so that the drug levels
in the body remain constant while the drug is being administered. More
recent transdermal drug delivery mechanisms follow the Higuchi mod-
el.22 As will be shown in subsequent sections, nanostructured polymeric
and silica nanoparticles are being developed as drug carriers which
achieve near zero-order kinetics:
Zero order : DtD0 k0tFirst order : lnDt lnD0 k1t
Higuchi : DtD0 kHt12
(1)
where Dt
is the amount of drug released at time t, D0 is the initial amount
of drug released, result of initial rapid release, k0 is the zero-order release
DM, June 2005 345
8/3/2019 Nanostructure-Mediated Drug Delivery
5/20
constant, k1 is the first-order release constant, and kH is the Higuchi
release constant.Various nanoscale architectures can be realized including solid spheres,
hollow spheres, tubes, porous particles, solid particles, and branched
structures. To achieve such nanostructures, different fabrication methodsare used depending on the type of material. The methods used for
nanoscale assembly include molecular self-assembly,23 bioaggregation,24
nanomanipulation,25 photochemical patterning,26 molecular imprinting,26
layer-by-layer electrostatic deposition,27,28 and vapor deposition.29
Biologic StructuresThe biologic world is full of nanostructures. Researchers are now
devising ways to mimic, enhance, and harness the functionality of these
biologic nanostructures.30,31 Scanning probe manipulation25 and photo-
chemical patterning26 are examples of nonbiologic techniques used toform nanostructures out of biologic materials. Furthermore, techniques
mimicking biologic actions such as molecular self-assembly23,32 and
biologic aggregation24 are used to create nanostructures.Biologic nanostructures that have been developed for drug delivery
purposes include lipid nanotubes,33 lipid nanospheres,34-36 lipid nanopar-ticles,37-39 lipid emulsions,40-42 circular peptides,43,44 chitosan,45-48 viral
nanoparticles,49 and nucleic acid nanostructures.50 One of the mostinvestigated lipid forms is the liposome, which is a hollow vesicle that can
FIG 1. Drug release profiles from zero order, first order, and Higuchi kinetics.
346 DM, June 2005
8/3/2019 Nanostructure-Mediated Drug Delivery
6/20
be used to entrap and release drug molecules.51-55 Multicompartment
liposomes have also been fabricated54 that may provide a means forextended drug release. Biologics that have been developed or are being
investigated by use of delivery systems that are based on biologic
nanostructures include genes, small interfering RNA (siRNA), andgrowth hormones.
Polymer StructuresPolymer materials exhibit several desirable properties for drug carrier
use including biocompatibility, biodegradability, and functionalizationcapability. Through functionalization and structural manipulation of
polymer materials, drug molecules can be incorporated within thepolymer. Entrapping or encapsulating the drug within a polymer allows
for greater control of the pharmacokinetic behavior of the active drug
molecule. The drug can be released with a more ideal, near zero-orderkinetic profile, which establishes a more constant flow of the drug out of
the carrier. This pharmacokinetic behavior maintains more appropriatesteady levels of the drug at the site of delivery. In contrast, conventional
oral drug delivery typically follows first-order release kinetics where the
drug release rate is proportional to the amount of drug remaining in thedrug carrier. Landgraf et al.56 have compared the release kinetics of an
anti-inflammatory agent taken orally by use of a macroporous copolymercarrier and a microporous copolymer carrier containing nanochannels.
The macroporous drug carrier releases the drug with an initial burst and
follows first-order release kinetics. The microporous carrier structuredwith nanochannels steadily releases the drug in near zero-order fashion.
Techniques that are used to couple the drug with the polymer include
sequestering, conjugation, and micelle formation.57 Nanostructure forma-tion of polymers has been accomplished through mold replication,58
colloidal lithography,59 interfacial polymerization,60 nanoprecipitation,60
multiple solvent emulsion evaporation,60 nanoimprinting,61 and electro-
spinning.62
A review of biodegradable polymeric materials that show promise fordrug delivery applications is compiled in Ulrich et al.63 Biodegradable
polymer nanoparticles, typically consisting of polylactic acid (PLA),
polyglycolic acid (PGA), or a copolymer of PLA and PGA, are beinginvestigated for the delivery of proteins and genes,64,65 vaccines,66,67
anticancer drugs,68-70 ocular drugs,71,72 and cytokines.73 Other polymersbeing investigated for nanoscale drug carriers include polyalkylcyanoac-
rylate,74 poly(3-hydroxybutanoic acid) (PHB),75 poly(organophospha-zene),76 poly(ethylene glycol) (PEG),77-80 poly(caprolactone) (PCL),81,82
DM, June 2005 347
8/3/2019 Nanostructure-Mediated Drug Delivery
7/20
poly(ethylene oxide) (PEO),83 and copolymers such as PLA-PEG.84,85
Synthetic polymers, such as PEG, can be used to encapsulate biologic
materials to create a more stable drug carrier. One example of a hybrid
drug carrier is a liposome coated with PEG, called a stealth liposome.Conventional liposomes are typically cleared rapidly from the blood.
Stealth liposomes, with PEG coatings, can have prolonged circulationtimes.52 The mechanisms behind prolonged circulation are still being
investigated. Additionally, polymers are being used to enhance the releasecharacteristics of another drug carrier as in the coating of tablets with
hydroxypropyl methylcellulose phthalate (HPMCP) nanoparticles.86 The
nanoparticle-coated tablets show a decrease in release rate and a migra-
tion towards zero-order release kinetics as the particle size is decreased,as shown in Figure 2.
DendrimersDendrimers, a unique class of polymers, are highly branched macromole-
cules whose size and shape can be precisely controlled.87,88 Dendrimers are
FIG 2. Effect of HPMCP nanoparticle size on release behavior of coated diclofenac tablets.Particle diameters: closed circles, 810 nm; open squares, 590 nm; closed triangles, 335 nm;inverted open triangles, 220 nm; plus sign, 171 nm. Reprinted with permission from Journal ofControlled Release.86 Copyright 2003, Elsevier Inc.
348 DM, June 2005
8/3/2019 Nanostructure-Mediated Drug Delivery
8/20
fabricated from monomers using either convergent or divergent step-growth
polymerization. Two representations of polyamidoamine-based dendrimers
are shown in Figure 3. The well-defined structure, monodispersity of size,surface functionalization capability, and stability are properties of dendrimers
that make them attractive drug carrier candidates. Drug molecules can be
incorporated into dendrimers via either complexation or encapsulation asshown in Figure 4. Dendrimers are being investigated for both drug and gene
delivery,89,90 as carriers for penicillin,91 and for use in anticancer ther-apy.92,93 Dendrimers used in drug delivery studies typically incorporate one
or more of the following polymers: polyamidoamine (PAMAM),94,95 mel-amine,96 poly(L-glutamic acid) (PG),97 polyethyleneimine (PEI),97 poly(pro-
FIG 3. Example chemical structure of a polyamidoamine dendrimer (left). Stick modelrepresentation of a polyamidoamine dendrimer (right).
FIG 4. Schematic of incorporation of drug within a dendrimer structure. Complexation
covalent attachment to end groups (left).
Encapsulationtrapment inside dendrimer core (right).
DM, June 2005 349
8/3/2019 Nanostructure-Mediated Drug Delivery
9/20
pylene imine),98 and poly(ethylene glycol) (PEG).98 Chitin and chitosan have
also been incorporated with dendrimers.99 For further review on dendrimers,see Aulenta et al.100
Silicon-Based StructuresSilicon-based structures can be fabricated by photolithography, etching,
and deposition techniques commonly used in the manufacture of semi-conductors and microelectromechanical systems (MEMS). The most
commonly investigated silicon-based materials for drug delivery are
porous silicon and silica, or silicon dioxide. Architectures includecalcified nanopores, platinum-containing nanopores, porous nanopar-
ticles, and nanoneedles.101 Figure 5 shows a nanoporous membranefabricated on a silicon substrate.102 The density and diameter of the
nanopores can be accurately controlled to achieve a constant drug
delivery rate through the pores.Porous hollow silica nanoparticles (PHSNP) are fabricated in a suspen-
sion containing sacrificial nanoscale templates such as calcium carbon-ate.103 Silica precursors, such as sodium silicate, are added into the
suspension, which is then dried and calcinated creating a core of the
template material coated with a porous silica shell. The template materialis then dissolved in a wet etch bath, leaving behind the porous silica shell.
Creation of drug carriers involves the mixing of the PHSNPs with thedrug molecule and subsequently drying the mixture to coalesce the drug
molecules to the surface of the silica nanoparticles as shown in Figure 6.
Through controlling the pore size and the particle diameter, the releasekinetics approach near zero-order as shown in Figure 7, where the release
behavior of conventional silica nanoparticles is compared with that of
porous hollow silica nanoparticles. As shown, the porous hollow nano-particles exhibit a much more desirable gradual release.104
Examples of therapies being investigated for use with silicon-baseddelivery systems include porous silicon embedded with platinum as an
antitumor agent,105 calcified porous silicon designed as an artificial
growth factor,106 silicon nanopores for antibody delivery,102,107 andporous silica nanoparticles containing antibiotics,108 enzymes,109 and
DNA.110
Carbon StructuresTwo nanostructures, shown in Figure 8, that have received much
attention in recent years are hollow, carbon-based, cage-like architec-
tures: nanotubes and fullerenes, also known as buckyballs because of theirspherical structure resembling the geodesic domes of Buckminster Fuller.
350 DM, June 2005
8/3/2019 Nanostructure-Mediated Drug Delivery
10/20
FIG 5. Nanoporous membrane with 24.5-nm pores. Reprinted with permission from Advancesin Drug Delivery Reviews.102 Copyright 2003, Elsevier Inc.
FIG 6. Preparation of hollow silica nanoparticle-based drug carriers. A, Silica nanoparticle. B,Suspend drug molecule with silica nanoparticle. C, Dry mixture to entrap drug molecule.Reprinted with permission from Biomaterials.103 Copyright 2004, Elsevier Inc.
DM, June 2005 351
8/3/2019 Nanostructure-Mediated Drug Delivery
11/20
Single-wall nanotubes (SWNTs), multiwall nanotubes (MWNTs), and
C60 fullerenes are common configurations. The size, geometry, and
surface characteristics of these structures make them appealing for drugcarrier usage. SWNTs and C60 fullerenes have diameters on the order of
1 nm, about half the diameter of the average DNA helix. MWNTs have
diameters ranging from several nanometers to tens of nanometers depend-ing on the number of walls in the structure. Fullerenes and carbon
nanotubes are typically fabricated using electric arc discharge (EAD),laser ablation (LA), chemical vapor deposition (CVD), or combustion
processes.29,111,112
Surface-functionalized carbon nanotubes (CNTs) can be internalized
within mammalian cells,113 and when linked to peptides may be used as
vaccine delivery structures.114,115 With use of molecular dynamics (MD)
simulations, the flow of water molecules through CNTs has beenmodeled,116-118 and implies their potential use as small molecule trans-porters. Other simulations have involved the transport of DNA through
CNTs, indicating potential use as a gene delivery tool.119 Figure 9 shows
a snapshot from an MD simulation of molecular water flow throughsingle-wall CNTs.117
FIG 7. Comparison of release profiles of conventional silica nanoparticles and porous hollowsilica nanoparticles. Chemical released was BB (brilliant blue F). Reprinted with permission from
Journal of Controlled Release.104 Copyright 2004, Elsevier Inc.
352 DM, June 2005
8/3/2019 Nanostructure-Mediated Drug Delivery
12/20
Much work with CNTs has involved composite materials. For example,
temperature-stabilized hydrogels for drug delivery applications incorpo-
rate CNTs.120 Fullerenes have also shown drug targeting capability.
Tissue-selective targeting121 and intracellular targeting of mitochon-dria122 have been shown with use of fullerene structures. Furthermore,experiments with fullerenes have also shown that they exhibit antioxi-
dant123,124 and antimicrobial behavior.125
Metal StructuresHollow metal nanoshells are being investigated for drug delivery
applications.126 Typical fabrication methods involve templating of the
thin metal shell around a core material such as a silica nanoparticle.Typical metals include gold, silver, platinum, and palladium. When
linked to or embedded within polymeric drug carriers, metal nanoparticlescan be used as thermal release triggers when irradiated with infrared light
or excited by an alternating magnetic field.127 Biomolecular conjugationmethods of metals include bifunctional linkages, lipophilic interaction,
FIG 8. Ball-and-stick model of a single-wall carbon nanotube (left).
Reprinted with permissionfrom Precision Engineering.29 Copyright 2004, Elsevier Inc. Model of a fullerene molecule(right). Reprinted from Proceedings of the National Academy of Sciences of the United Statesof America.112 Copyright 2000, National Academy of Sciences, USA.
DM, June 2005 353
8/3/2019 Nanostructure-Mediated Drug Delivery
13/20
silanization, electrostatic attraction, and nanobead interactions.128 Figure
10 shows examples of silanization and electrostatic attraction methods of
metal nanoparticle conjugation.
ConclusionsAs we gain more knowledge with respect to disease pathophysiology
and cellular mechanisms, more specific drugs are being developed. To usethe specificity and potency of these drugs, new drug delivery systems
must be implemented. Nanostructured delivery architectures are promis-ing candidates that will enable efficient and targeted delivery of novel
FIG 9. Simulation snapshot of water molecule flow through single-wall carbon nanotubes. Insetat top right: Close-up view within a single nanotube. Reprinted from Proceedings of the National
Academy of Sciences of the United States of America.117
Copyright 2003, National Academyof Sciences, USA.
354 DM, June 2005
8/3/2019 Nanostructure-Mediated Drug Delivery
14/20
drug compounds. Sustained drug release and intracellular entry capability
are properties of nanoscale drug delivery mechanisms that will minimize
side effects and allow for the direct treatment of the cause of the diseaserather than the symptoms of the disease.
REFERENCES
1. Kefalides PT. New methods for drug delivery. Ann Intern Med 1998;128:1053-5.
2. Bradbury J. Beyond pills and jabs. Lancet 2003;362:1984-5.
3. Henry CM. New wrinkles in drug delivery. Chem Eng News 2004;82:37-42.
4. VisionGain. Drug delivery 2003: new technologies in the global market. Vision-
Gain, June 2003.
5. El-Aneed A. An overview of current delivery systems in cancer gene therapy. JControlled Release 2004;94:1-14.
6. DAquino R. Good drug therapy: its not just the moleculeits the delivery. CEP
Magazine 2004;100:15S-7S.
7. Roco MC. The US National Nanotechnology Initiative after 3 years (2000-2003).
J Nanoparticle Res 2004;6:1-10.
8. Dubin CH. Special delivery: pharmaceutical companies aim to target their drugs
with nano precision. Mech Eng Nanotechnol 2004;126(suppl):10-2.
9. Dass CR, Su T. Particle-mediated intravascular delivery of oligonucleotides to
tumors: associated biology and lessons from genotherapy. Drug Delivery2001;8:191-213.
10. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent
developments and prospects. Crit Rev Ther Drug Carrier Syst 2002;19:425-98.
11. Senior K. bNano-dumplingQ with drug delivery potential. Mol Med Today
1998;4:321.
12. LaVan DA, Lynn DM, Langer R. Moving smaller in drug discovery and delivery.
Nat Rev Drug Discovery 2002;1:77-84.
13. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery.
Nat Biotechnol 2003;21:1184-91.
14. Ravi Kumar MN. Nano and microparticles as controlled drug delivery devices.J Pharm Pharm Sci 2000;3:234-58.
15. Desai MP. Gastrointestinal uptake of biodegradable microparticles: effect of
particle size. Pharm Res 1996;13:1838-45.
16. Hussain N, Jaitley V, Florence AT. Recent advances in the understanding of uptake
of microparticulates across the gastrointestinal lymphatics. Adv Drug Delivery Rev
2001;50:107-42.
FIG 10. Nanoparticle bioconjugation methods: (1) silanization, and (2) electrostatic attraction.
DM, June 2005 355
8/3/2019 Nanostructure-Mediated Drug Delivery
15/20
17. Kohli AK, Alpar HO. Potential use of nanoparticles for transcutaneous vaccine
delivery: effect of particle size and charge. Int J Pharm 2004;275:13-7.
18. Brzoska M, Langer K, Coester C, et al. Incorporation of biodegradable nanopar-
ticles into human airway epithelial cells-in vitro study of the suitability as a vehiclefor drug or gene delivery in pulmonary diseases. Biochem Biophys Res Commun
2004;318:562-70.
19. Martin CR, Kohli P. The emerging field of nanotube biotechnology. Nat Rev Drug
Discovery 2003;2:29-37.
20. Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of
chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51:691-743.
21. Moselhy J, Wu XY, Nicholov R, et al. In vitro studies of the interaction of
poly(NIPAm/MAA) nanoparticles with proteins and cells. J Biomat Sci Polym Ed
2000;11:123-47.22. Costa P, Sousa Lobo JM. Evaluation of mathematical models describing drug
release from estradiol transdermal systems. Drug Dev Ind Pharm 2003;29:89-97.
23. Zhang S. Emerging biological materials through molecular selfassembly. Biotech-
nol Adv 2002;20:321-39.
24. Mirkin CA, Letsinger RL, Mucic RC, et al. A DNA method for rationally
assembling nanoparticles into macroscopic materials. Nature 1996;382:607-9.
25. Hansma HG, Kasuya K, Oroudjev E. Atomic force microscopy imaging and pulling
of nucleic acids. Curr Opin Struct Biol 2004;14:380-5.
26. Cui D. Advance and prospect of bionanomaterials. Biotechnol Prog
2003;19:683-92.
27. Ai H. Biomedical applications of electrostatic layer-by-layer nanoassembly of
polymers, enzymes, and nanoparticles. Cell Biochem Biophys 2003;39:23-43.
28. Ai H. Electrostatic layer-by-layer nanoassembly on biological microtemplates:
platelets. Biomacromolecules 2002;3:560-4.
29. Mamalis AG, Vogtl7nder LOG, Markopoulos A. Nanotechnology and nanostruc-
tured materials: trends in carbon nanotubes. Precision Eng 2004;28:16-30.
30. Lowe CR. Nanobiotechnology: the fabrication and applications of chemical and
biological nanostructures. Curr Opin Struct Biol 2000;10:428-34.
31. Lanyi JK. Proton pumps: mechanism of action and applications. Trends Biotechnol2001;19:140-4.
32. Zhang S, Marini DM, Hwang W, et al. Design of nanostructured biological
materials through self-assembly of peptides and proteins. Curr Opin Chem Biol
2002;6:865-71.
33. Cans A-S, Wittenberg N, Karlsson R, et al. Artificial cells: unique insights into
exocytosis using liposomes and lipid nanotubes. Proc Natl Acad Sci USA
2003;100:400-4.
34. Tomii Y. Lipid formulations as a drug carrier for drug delivery. Curr Pharm Design
2002;8:467-74.35. Fukui H, Koike T, Saheki A, et al. Evaluation of the efficacy and toxicity of
amphotericin B incorporated in lipid nano-sphere (LNS). Int J Pharm
2003;263:51-60.
36. Fukui H, Koike T, Nakagawa T, et al. Comparison of LNS-AmB, a novel low-dose
formulation of amphotericin B with lipid nano-sphere (LNS), with commercial
lipid-based formulations. Int J Pharm 2003;267:101-12.
356 DM, June 2005
8/3/2019 Nanostructure-Mediated Drug Delivery
16/20
37. Seki J, Sonoke S, Saheki A, et al. Lipid transfer protein transports compounds from
lipid nanoparticles to plasma lipoproteins. Int J Pharm 2004;275:239-48.
38. Seki J. A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug
carrier for passive drug targeting. Int J Pharm 2004;273:75-83.39. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug
Delivery Rev 2004;56:675-711.
40. Fang J-Y, Leu Y-L, Chang C-C, et al. Lipid nano/submicron emulsions as vehicles
for topical flurbiprofen delivery. Drug Delivery 2004;11:97-105.
41. Lundberg BB, Risovic V, Ramaswamy M, et al. A lipophilic paclitaxel derivative
incorporated in a lipid emulsion for parenteral administration. J Controlled Release
2003;86:93-100.
42. Kayser O, Kiderlin AF. Delivery strategies for antiparasitics. Expert Opin Invest
Drugs 2003;12:197-207.43. Fernandez-Lopez S, Kim H-S, Choi EC, et al. Antibacterial agents based on the
cyclic D. L-apeptide architecture. Nature 2001;412:452-5.
44. Djalali R, Samson J, Matsui H. Doughnut-shaped peptide nanoassemblies and their
applications as nanoreactors. J Am Chem Soc 2004;126:7935-9.
45. Mao S, Shuai X, Unger F, et al. The depolymerization of chitosan: effects on
physicochemical and biological properties. Int J Pharm 2004;281:45-54.
46. Park JH, Kwon S, Nam J-O, et al. Self-assembled nanoparticles based on glycol
chitosan bearing 5hcholanic acid for RGD peptide delivery. J Controlled Release
2004;95:579-88.
47. Van der Lubben IM. Chitosan and its derivatives in mucosal drug and vaccine
delivery. Eur J Pharm Sci 2001;14:201-7.
48. Bozkir A, Saka OM. Chitosan nanoparticles for plasmid DNA delivery: effect of
chitosan molecular structure on formulation and release characteristics. Drug
Delivery 2004;11:107-12.
49. Yamada T, Ueda M, Seno M, et al. Novel tissue and cell type-specific gene/drug
delivery system using surface engineered Hepatitis B virus nano-particles. Curr
Drug Targets Infect Disorders 2004;4:163-7.
50. Niemeyer CM. Semi-synthetic nucleic acid-protein conjugates: applications in life
sciences and nanobiotechnology. Rev Mol Biotechnol 2001;82:47-66.51. Barza M, Stuart M, Szoka F. Effect of size and lipid composition on the
pharmacokinetics of intravitreal liposomes. Invest Ophthalmol Visual Sci
1987;28:893-900.
52. Moghimi SM, Szebeni J. Stealth liposomes and long circulation nanoparticles:
critical issues in pharmacokinetics, opsonization and protein-binding properties.
Prog Lipid Res 2003;42:463-78.
53. Peer D. Loading mitomycin C inside long circulating hyaluronan targeted nano-
liposomes increases its antitumor activity in three mice tumor models. Int J Cancer
2004;108:780-9.54. Coldren B, Boyer C, Kisak ET, et al. The vesosome-a multicompartment drug
delivery vehicle. Curr Med Chem 2004;11:199-219.
55. Cevc G. Hydration-driven transport of deformable lipid vesicles through fine pores
and the skin barrier. Biophys J 2003;84:1010-24.
56. Landgraf W, Li N-H, Benson JR. Polymer microcarrier exhibiting zero-order
release. Drug Delivery Technol 2003;3.
DM, June 2005 357
8/3/2019 Nanostructure-Mediated Drug Delivery
17/20
57. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discovery
2003;2:347-60.
58. Li YY, Cunin F, Link JR, et al. Polymer replicas of photonic porous silicon for
sensing and drug delivery applications. Science 2003;299:2045-8.59. Dalby MJ, Berry CC, Riehle MO, et al. Attempted endocytosis of nano-environ-
ment produced by colloidal lithography by human fibroblasts. Exp Cell Res
2004;295:387-94.
60. Couvreur P, Barratt G, Fattal E, et al. Nanocapsule technology: a review. Crit Rev
Ther Drug Carrier Syst 2002;19: 99-134.
61. Lu Y, Chen SC. Micro and nano-fabrication of biodegradable polymers for drug
delivery. Adv Drug Delivery Rev 2004;56:1621-33.
62. Frenot A, Chronakis IS. Polymer nanofibers assembled by electrospinning. Curr
Opin Colloid Interface Sci 2003;8:64-75.
63. Ulrich KE, Cannizzaro SM, Langer RS, et al. Polymeric systems for controlled
drug release. Chem Rev 1999;99: 3181-98.
64. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery
to cells and tissue. Adv Drug Delivery Rev 2003;55: 329-47.
65. Panyam J, Dali MM, Sahoo SK, et al. Polymer degradation and in vitro release of
a model protein from poly(d,l-lactide-co-glycolide) nano-and microparticles. J
Controlled Release 2003;92:173-87.
66. Nugent J, Wan Po AL, et al. Design and delivery of nonparenteral vaccines. J Clin
Pharm Ther 1998;23:257-85.
67. Katare YK, Panda AK, Lalwani K, et al. Potentiation of immune response frompolymer-entrapped antigen: toward development of single dose tetanus toxoid
vaccine. Drug Delivery 2003;10:231-8.
68. Lee KE, Kim BK, Yuk SH. Biodegradable polymeric nanospheres formed by
temperature-induced phase transition in a mixture of poly(lactide-co-glycolide) and
poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copoly-
mer. Biomacromolecules 2002;3:1115-9.
69. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer
therapy. Adv Drug Delivery Rev 2004;56:1649-59.
70. Rosiak JM, Janik I, Kadlubowski S, et al. Nano-, micro-and macroscopic hydrogels
synthesized by radiation technique. Nucl Instruments Methods Phys Res B
2003;208:325-30.
71. Ggiannavola C, Bucolo C, Maltese A, et al. Influence of preparation conditions on
acyclovirloaded poly-d,l-lactic acid nanospheres and effect of PEG coating on
ocular drug bioavailability. Pharm Res 2003;20:584-90.
72. Kompella UB. Subconjunctival nano-and microparticles sustain retinal delivery of
budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest
Ophthalmol Visual Sci 2003;44:1192-201.
73. Sanchez A, Tobio M, Gonzalez L, et al. Biodegradable micro-and nanoparticles as
long-term delivery vehicles for interferon-alpha. Eur J Pharm Sci 2003;18:221-9.74. Salgueiro A, Gamisans F, Espina M, et al. Cyclophosphamide-loaded nanospheres:
analysis of the matrix structure by thermal and spectroscopic methods. J Microen-
capsulation 2002;19:305-10.
75. Piddubnyak V, Kurcok P, Matuszowicz A, et al. Oligo-3-hydroxybutyrates as
potential carriers for drug delivery. Biomaterials 2004;25:5271-9.
76. Kim JI, Jun YJ, Seong J-Y, et al. Synthesis and characterization of nanosized
358 DM, June 2005
8/3/2019 Nanostructure-Mediated Drug Delivery
18/20
poly(organophosphazenes) with methoxy-poly(ethylene glycol) and dipeptide
ethyle esters as side groups. Polymer 2004;45:7083-9.
77. Moghimi SM. Capture of stealth nanoparticles by the bodys defences. Crit Rev
Ther Drug Carrier Syst 2001;18:527-50.78. Kumar R, Ming-Hsiung C, Parmar VS, et al. Supramolecular assemblies based on
copolymers of PEG600 and functionalized aromatic diesters for drug delivery
applications. J Am Chem Soc 2004;126:10640-4.
79. Vila A, Gill H, McCallion O, et al. Transport of PLA-PEG particles across the nasal
mucosa: effect of particle size and PEG coating density. J Controlled Release
2004;98:231-44.
80. Luu YK. Development of a nanostructured DNA delivery scaffold via electrospin-
ning of PLGA and PLA-PEG block copolymers. J Controlled Release
2003;89:341-53.
81. Zhang L, Hu Y, Jiang X, et al. Camptothecin derivative-loaded poly(caprolactone-
co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodis-
tribution in mice. J Controlled Release 2004;96:135-48.
82. Rodrigues JS, Santos-Magalhaes NS, Coelho LCBB, et al. Novel core(polyester)-
shell(polysaccharide) nanoparticles: protein loading and surface modification with
lectins. J Controlled Release 2003;92:103-12.
83. Van Domeselaar GH, Kwon GS, Andrew LC, et al. Application of solid phase
peptide synthesis to engineering PEOpeptide block copolymers for drug delivery.
Colloids Surfaces B Biointerfaces 2003;30:323-34.
84. Panoyan A, Quesnel R, Hildgen P. Injectable nanospheres from a novel multiblockcopolymer: cytocompatibility, degradation and in vitro release studies. J Microen-
capsulation 2003;20:745-58.
85. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and
pharmaceutical applications. Adv Drug Delivery Rev 2003;55:403-19.
86. Kim IH, Park JH, Cheong IW, et al. Swelling and drug release behavior of tablets
coated with aqueous hydroxypropyl methylcellulose phthalate (HPMCP) nanopar-
ticles. J Controlled Release 2003;89:225-33.
87. Pricl S, Fermeglia M, Ferrone M, et al. Scaling properties in the molecular structure
of three-dimensional, nanosized phenylenebased dendrimers as studied by atomistic
molecular dynamics simulations. Carbon 2003;41:2269-83.
88. Namazi H, Adeli M. Dendrimers of citric acid and poly(ethylene glycol) as the new
drug-delivery agents. Biomaterials 2004;26: 1175-83.
89. Cloninger MJ. Biological applications of dendrimers. Curr Opin Chem Biol
2002;6:742-6.
90. Hussain M, Shchepinov M, Sohail M, et al. A novel anionic dendrimer for
improved cellular delivery of antisense oligonucleotides. J Controlled Release
2004;99:139-55.
91. Yang H, Lopina ST. Penicillin V-conjugated PEG-PAMAM star polymers.
J Biomat Sci Polym Ed 2003;14:1043-56.92. Quintana A, Raczka E, Piehler L, et al. Design and function of a dendrimer-based
therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm
Res 2002; 19:1310-6.
93. Meijer EW, Van Genderen MHP. Chemistry: dendrimers set to selfdestruct. Nature
2003;426:128-9.
94. Kannan S, Kolhe P, Raykova V, et al. Dynamics of cellular entry and drug delivery
DM, June 2005 359
8/3/2019 Nanostructure-Mediated Drug Delivery
19/20
by dendritic polymers into human lung epithelial carcinoma cells. J Biomat Sci
Polym Ed 2004;15:311-30.
95. Jevprasesphant R, Penny J, Attwood D, et al. Transport of dendrimer nanocarriers
through epithelial cells via the transcellular route. J Controlled Release2004;97:259-67.
96. Neerman MF, Zhang W, Parrish AR, et al. In vitro and in vivo evaluation of a
melamine dendrimer as a vehicle for drug delivery. Int J Pharm 2004;281:129-32.
97. Tansey W, Ke S, Cao XY, et al. Synthesis and characterization of branched
poly(L-glutamic acid) as a biodegradable drug carrier. J Controlled Release
2004;94:39-51.
98. Paleos CM, Tsiourvas D, Sideratou Z, et al. Acid-and salttriggered multifunctional
poly(propylene imine) dendrimer as a prospective drug delivery system. Biomac-
romolecules 2004;5:524-9.99. Sashiwa H, Aiba S-I. Chemically modified chitin and chitosan as biomaterials. Prog
Polymer Sci 2004;29:887-908.
100. Aulenta F, Hayes W, Rannard S. Dendrimers: a new class of nanoscopic containers
and drug delivery devices. Eur Polym J 2003;39:1741-71.
101. Prinz AV, Prinz VYa, Seleznev VA. Semiconductor micro- and nanoneedles for
microinjections and ink-jet printing. Microelectron Eng 2003;67-68:782-8.
102. Tao SL, Desai TA. Microfabricated drug delivery systems: from particles to pores.
Adv Drug Delivery Rev 2003;55:315-28.
103. Chen J-F, Ding H-M, Wang J-X, Shao L. Preparation and characterization of
porous hollow silica nanoparticles for drug delivery application. Biomaterials
2004;25:723-7.
104. Li Z-Z, Wen L-X, Shao L, et al. Fabrication of porous hollow silica nanoparticles
and their applications in drug release control. J Controlled Release 2004;98:245-54.
105. Li X, St John J, Coffer JL, et al. Porosified silicon wafer structures impregnated
with platinum antitumor compounds: fabrication, characterization, and diffusion
studies. Biomed Microdevices 2000;2:265-72.
106. Weis RP, Montchamp J-L, Coffer JL, et al. Calcified nanostructured silicon wafer
surfaces for biosensing: effects of surface modification on bioactivity. Dis Markers
2002;18:159-65.107. Leoni L, Desai TA. Micromachined biocapsules for cell-based sensing and
delivery. Adv Drug Delivery Rev 2004;56:211-29.
108. Chen JF, Ding HM, Wang JX, et al. Preparation and characterization of porous
hollow silica nanoparticles for drug delivery application. Biomaterials
2004;25:723-7.
109. Jain TK, Roy I, De TK, et al. Nanometer silica particles enacapsulating active
compounds: a novel ceramic drug carrier. J Am Chem Soc 1998;120:11092-5.
110. Sameti M, Bohr G, Ravi Kumar MN, et al. Stabilisation by freeze-drying of
cationically modified silica nanoparticles for gene delivery. Int J Pharm2003;266:51-60.
111. Gogotsi Y, Naguib N, Libera LA. In situ chemical experiments in carbon
nanotubes. Chem Phys Lett 2002;365:354-60.
112. Becker L, Poreda RJ, Bunch TE. An extraterrestrial carbon carrier phase for noble
gases. Proc Natl Acad Sci USA 2000;97: 2979-83.
113. Shi Kam NW, Jessop TC, Wender PA, et al. Nanotube molecular transporters:
360 DM, June 2005
8/3/2019 Nanostructure-Mediated Drug Delivery
20/20
internalization of carbon nanotube-protein conjugates into mammalian cells. J Am
Chem Soc 2004;126:6850-1.
114. Pantarotto D, Partidos CD, Hoebeke J, et al. Immunization with peptide-function-
alized carbon nanotubes enhances virus-specific neutralizing antibody responses.Chem Biol 2003;10:961-9.
115. Panhuis M. Vaccine delivery by carbon nanotubes. Chem Biol 2003;10:897-8.
116. Truskett TM. The subtleties of water in small spaces. Proc Natl Acad Sci USA
2003;100:10139-40.
117. Kalra A, Garde S, Hummer G. Osmotic water transport through carbon nanotube
membranes. Proc Natl Acad Sci USA 2003;100:10175-80.
118. Zhu F, Schulten K. Water and proton conduction through carbon nanotubes as
models for biological channels. Biophys J 2003;85:236-44.
119. Gao H, Kong Y, Cui D. Spontaneous insertion of DNA oligonucleotides into
carbon nanotubes. Nano Lett 2003;3:471-3.
120. Li H, Wang DQ, Liu BL, et al. Synthesis of a novel gelatincarbon nanotubes hybrid
hydrogel. Colloids Surfaces B Biointerfaces 2004;33:85-8.
121. Gonzalez KA, Wilson LJ, Wu W, et al. Synthesis and in vitro characterization of
a tissue-selective fullerene: vectoring C(60)(OH)(16)AMBP to mineralized bone.
Bioorganic Med Chem 2002;10:1991-7.
122. Foley S, Crowley C, Smaihi M, et al. Cellular localization of a water-soluble
fullerene derivative. Biochem Biophys Res Commun 2002;294:116-9.
123. Lin AMY, Chyi BY, Wang SD, et al. Carboxyfullerene prevents iron-induced
oxidative stress in rat brain. J Neurochem 1999;72:1634-40.124. Fumelli C, Marconi A, Salvioli S, et al. Carboxyfullerenes protect human
keratinocytes from ultraviolet-B-induced apoptosis. J Invest Dermatol 2000;
115:835-41.
125. Tsao N, Luh T-Y, Chou C-K, et al. In vitro action of carboxyfullerene. J
Antimicrob Chemother 2002; 49:641-9.
126. Sun Y, Mayers BT, Xia Y. Template-engaged replacement reaction: a one-step
approach to the large scale synthesis of metal nanostructures with hollow interiors.
Nano Lett 2002;2:481-5.
127. Rfsler A, Vandermeulen GW, Klok HA. Advanced drug delivery devices via
self-assembly of amphiphilic block copolymers. Adv Drug Delivery Rev2001;53:95-108.
128. Bagwe RP, Zhao X, Tan W. Bioconjugated luminescent nanoparticles for biolog-
ical applications. J Dispersion Sci Technol 2003; 24:453-64.